VYEPTI® 
(eptinezumab) is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1Prescribing information and adverse event reporting can be accessed via the tabs at the top of this page.
THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY. IF YOU ARE A MEMBER OF THE PUBLIC/PATIENT PLEASE CLICK HERE.
VYEPTI® (eptinezumab) is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1Prescribing information and adverse event reporting can be accessed via the tabs at the top of this page.
Migraine can leave patients confined to the dark, and cut off from their everyday lives.2,5 Explore this impact in two different patients,* and see how VYEPTI could help.
*Fictional patients used for illustrative purposes.
This is not a current GB/EU pack and is for illustration purposes only.
Learn more about the benefit of VYEPTI for patients with episodic or chronic migraine, with key efficacy and tolerability data, and dosing information.
Keep up to date with the latest information from the world of migraine, including expert opinion, educational resources and details of upcoming events.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Lundbeck Limited, Medical Information, on: 01908 638972 or Email: SafetyLuUnitedKingdom@lundbeck.com
CGRP, calcitonin gene-related peptide.
